A limited market release of SpaceOAR Flex is expected to begin in the US later this year.
|Articles|November 1, 2004
High free testosterone may be linked with PCa risk
Baltimore-Relatively high levels of free testosterone in older men appear linked to a significantly increased risk for prostate cancer-a finding that raises the possibility that testosterone replacement might affect the risk of prostate cancer, reported J. Kellogg Parsons, MD, an instructor in the department of urology, Johns Hopkins University, Baltimore.
Advertisement
Advertisement
Related to this article
The PDUFA target action date is in the fourth quarter of 2026.
The approval is supported by data from the phase 3 LITESPARK-011 trial.
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
The AACU and the WOCN Society urge CMS to protect access to individualized catheter and ostomy supplies as competitive bidding begins in 2028.
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves belzutifan plus lenvatinib for advanced clear cell renal cell carcinoma
2
FDA grants priority review to perioperative durvalumab plus enfortumab vedotin in MIBC
3
After curative-intent treatment, prostate cancer recurrence is still an unmet need
4
Sandip Prasad, MD, on patient selection for chemoablation in LG-IR-NMIBC
5